BioNTech Results Presentation Deck
Expansion into New Class of Precision Antibacterials with PhagoMed Acquisition
D
........
36
●
●
●
●
●
●
PhagoMed: based in Vienna, Austria
Pioneering new class of precision antibacterials called synthetic lysins.
Lysins are highly bactericidal phage-derived enzymes that cleave the bacterial cell wall
Potential to address difficult to target pathogens & global challenge of antimicrobial resistance.
Lysin Builder in silico technology platform based on proprietary algorithms
Designed to rapidly produce recombinant natural lysins against a wide range of pathogens
Optimization for potency, stability and manufacturing yield
Total consideration can reach up to €150.0 m consisting of upfront consideration of €50.0 m (less)
acquired debt) with the possibility of the selling shareholders earning up to an additional ~ €100.0 m
Transaction closed in Q3
Forms BioNTech's new R&D hub for precision antibacterials operating as BioN Tech R&D Austria
mRNA Vaccines
Acquisition expands Infectious Disease Toolkit:
| mRNA Encoded Antibodies
....
Precision Anti-bacterials
BIONTECHView entire presentation